Immunopotentiators in Modern Vaccines (ePub)
56 DeutschlandCard Punkte sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Immunopotentiators in Modern Vaccines, Second Edition, provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants.
In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful.
- Provides contributions from leading international authorities in the field
- Features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system
- Lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator
- Offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines
Dr. Derek O’Hagan was the Global Head of Vaccine Chemistry and Formulation Research for Novartis Vaccines, based in Cambridge, MA until acquisition by GSK in March, 2015. He managed research teams (~50 total staff) in Cambridge and Siena, Italy. He originally qualified as a pharmacist in the UK, and is a former academic researcher who has worked on vaccine delivery in the industry since 1993. He was formerly a Lecturer in Drug Delivery at the Department of Pharmaceutical Sciences, University of Nottingham, UK, and received research funding from the World Health Organization, The Wellcome Trust and the Medical Research Council. He was recruited into the US in 1993, and moved to progress basic research into clinical evaluation, then subsequently worked on several vaccine delivery systems that were evaluated in the clinic, including novel adjuvants, nucleic acid vaccines and needle free vaccines. In the mid 1990’s, Dr. O’Hagan worked on the emulsion adjuvant MF59, which is now included in a licensed flu vaccine in more than 40 countries and is progressing towards licensure in the US. He has co-authored >140 original research publications, >60 book chapters and reviews and I
- 2016, 2. Auflage, 508 Seiten, Englisch
- Herausgegeben: Virgil Schijns, Derek O'Hagan
- Verlag: Elsevier Science & Techn.
- ISBN-10: 0128040955
- ISBN-13: 9780128040959
- Erscheinungsdatum: 02.11.2016
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
- Dateiformat: ePub
- Größe: 29 MB
- Mit Kopierschutz
- Vorlesefunktion
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Immunopotentiators in Modern Vaccines".
Kommentar verfassen